Robert Abouassaly

Robert Abouassaly, MD

Cleveland Clinic

Cleveland, Ohio

Dr. Abouassaly is an Associate Professor of Urology at the Cleveland Clinic in Cleveland, Ohio. He received his medical degree from the McGill University Faculty of Medicine in Montreal, Canada, in 2002. Dr. Abouassaly then went on to complete residencies in Surgery and Urology at the Cleveland Clinic, followed by a Fellowship in Urologic Oncology at the University of Toronto Faculty of Medicine.

He specializes in urology and has published widely about such urologic subjects as nephrectomy, prostate biopsy, and laparoscopic and robotic procedures. In addition to the Cleveland Clinic, Dr. Abouassaly is affiliated with University Hospitals Cleveland Medical Center and University Hospitals Richmond Medical Center.

Disclosures:

Talks by Robert Abouassaly, MD

An Overview of MRI Guided Biopsies for Prostate Cancer

Posted by Robert Abouassaly, MD | Feb 2018

Robert Abouassaly, MD, argues that the DECIPHER marker is not an ideal test for predicting patient’s response to chemotherapy. He cites the inconclusiveness of trials and research and the cost inefficiency of this biomarker. Also, he explains that the DECIPHER test’s classification system is based on RNA expression profiles, and not meant for therapeutic guidance. This is a counter argument to Alan H. Bryce’s lecture, “The DECIPHER Marker Can Predict Chemotherapy.”

Contemporary Management of Upper Tract Urothelial Carcinoma

Posted by Robert Abouassaly, MD | Jan 2018

Dr. Robert Aboussaly, MD, explains up-to-date approaches to treating upper tract urothelial carcinoma, including risk-stratification in diagnosis, nephroureterectomy, neoadjuvant chemotherapy, post-operative intravesical chemotherapy, and more.

Can the DECIPHER Marker Predict Chemotherapy?